Article History
Received: 17 February 2023
Revised: 18 March 2023
Accepted: 16 April 2023
First Online: 25 April 2023
Change Date: 11 May 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10067-023-06627-3
Declarations
:
: Anand Kumthekar and Maedeh Ashrafi declare no conflict of interest. Atul Deodhar: Consulting, Advisory Boards: AbbVie, Amgen, Aurinia, Bristol Myers Squibb, Eli Lilly, Janssen, MoonLake, Novartis, Pfizer, UCB. Research Grants: AbbVie, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, MoonLake, Novartis, Pfizer, UCB.